PK MED, a Lyon, France-based biotechnology firm, obtained €1.5M in non-dilutive DeepTech financing.
Bpifrance supplied the funding.
The corporate intends to make use of the funds to speed up its challenge PKM-02, an progressive cell-homing know-how aiming to reinforce bone marrow transplantation in a number of illnesses with excessive unmet medical want, equivalent to leukemias and hemoglobinopathies.
Led by CEO Gauthier Pouliquen, PK MED is a biotechnology firm, based in 2019 by Truffle Capital, creating injectable sensible implants for drug launch in rheumatology and cell homing for bone marrow transplantation. Its experience and technological know-how allow evolving current systemic remedies into new patented native therapies.
Its PKM-02 challenge relies on the event of a therapeutic implant domestically injected into the affected person’s bone marrow previous to allogeneic HSCT. This drug-based know-how, mixed with a biodegradable scaffold, is geared toward growing the homing of the transplanted cells, in addition to their subsequent engraftment. PKM-02 has proven in vitro outcomes, and PK MED is at present initiating preclinical research.
FinSMEs
24/07/2024
